Emergent BioSolutions Inc. (EBS) is a Gaithersburg, Maryland-based life sciences and biodefense company, best known for its NARCAN nasal spray for opioid overdose reversal and a portfolio of medical countermeasures that includes the ACAM2000 smallpox and mpox vaccine and anthrax vaccines such as BioThrax and CYFENDUS. After a volatile stretch, investors are asking whether the shares can climb back toward a double-digit price. The central question examined here is a $11 stock price target.
The $11 central target reflects three analyst price targets identified across S&P Global, StockAnalysis, and brokerage news, ranging from approximately $10 to $12. The average is $11, matching the figure reported independently by S&P Global. H.C. Wainwright (analyst Raghuram Selvaraju) reiterated a Buy rating and a $10 target in September 2026, having lowered it from $12 in August 2026 after a quarter that beat on revenue but missed on earnings. The firm cited generic erosion in the naloxone franchise as the reason for the cut.
The cautious side is meaningful: J.P. Morgan reinstated coverage of EBS with an Underweight rating in August 2026, assigning no price target while pointing to the company's transition phase and rising competition. In other words, the headline $11 average price target sits on a thin base of just three published targets and masks a genuine split between bulls focused on a biodefense turnaround and skeptics concerned about NARCAN's economics. It should be read as a directional benchmark, not a consensus guarantee.
Emergent BioSolutions shares recently closed near $6.36, giving the company a market capitalization of roughly $326 million. The stock trades well below its 52-week high near $14 and above its 52-week low around $4.36, reflecting a prolonged decline followed by partial stabilization. To reach $11 from $6.36, the stock would need to rise about 73%, which is a very large move by any standard and far exceeds the gap implied by a routine earnings beat.
The company's fundamentals remain challenged. Trailing twelve-month revenue is approximately $770 million, with a net loss of roughly $177 million and negative EPS (earnings per share). In its second-quarter 2026 report, management cut full-year 2026 adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $130-$150 million from $155-$175 million, citing NARCAN pricing and margin pressure, and recorded a $191 million non-cash impairment. Any credible path to $11 would likely require sustained NARCAN stabilization, growth in government countermeasure contracts, and a return toward profitability.
Several factors could underpin an advance. The company continues to secure meaningful public-health contracts, including a $52.7 million ACAM2000 modification and a roughly $24 million CYFENDUS award from the Biomedical Advanced Research and Development Authority (BARDA), plus a standing offer from the Government of Canada for NARCAN. A completed refinancing with a $150 million term loan extended maturities to 2031 and reduced interest costs, easing balance-sheet pressure. Management is also pursuing restructuring targeting about $40 million in annualized savings. Under CEO Joseph Papa, the company has refocused on medical countermeasures and cost discipline, and renewed global biosecurity concerns have periodically lifted demand for preparedness products.
The obstacles are substantial. NARCAN, historically the main revenue engine, faces generic competition and pricing pressure, with NARCAN gross margin reported to have fallen to around 10%. Revenue has declined for multiple years, and the company remains unprofitable on a trailing basis. The reduced 2026 EBITDA outlook signals that the competitive erosion is material. A high debt load, a 90-position workforce reduction, and the planned retirement of CFO Richard Lindahl at the end of 2026 add execution and transition risk. A risk-off shift in the broader market or any further government funding uncertainty could also compress the valuation of a small-cap, contract-dependent name.
From a market-structure perspective, the shares have been consolidating near the lower portion of their 52-week range after sliding from levels above $11 in 2025. The 52-week low near $4.36 stands as a key support level, while the $8-$9 zone, where the stock traded earlier in 2026, represents an initial resistance area on any recovery. The $10 psychological level and the $11 target sit above that band, meaning the stock would need to clear several overhead zones before the target becomes relevant.
Analyst price targets typically reflect a research horizon of about 12 months, though no single uniform date applies to all three targets used here. The most important near-term catalyst is the company's third-quarter 2026 earnings report on November 2, 2026, alongside updated commentary on NARCAN pricing, EBITDA guidance, and cost savings. Investors should also track new BARDA or government contract awards, any refinancing or debt developments, the CFO transition, and analyst target revisions, which have moved frequently for this stock.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. The tool is designed to help traders discover opportunities, keep watch on existing positions, and identify changing trends more efficiently than manual screening alone. For a volatile, small-cap name such as EBS, combining AI-generated signals with fundamental research can provide an additional layer of context for decision-making.
The $11 target is a plausible but demanding benchmark. It represents the average of just three published analyst price targets spanning $10 to $12, and it sits roughly 73% above the recent price of about $6.36. Supportive forces, including steady government contract wins and a cleaner balance sheet, are counterbalanced by NARCAN's competitive erosion, a lowered EBITDA outlook, and persistent losses. With a narrow target range, an Underweight rating in the mix, and a large required gain, the path to $11 is far from assured. Investors should weigh the biodefense contract momentum against the naloxone headwinds and watch the November earnings report and any target revisions closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -1.43% | ||
| SIGA - EBS | 40% Loosely correlated | -0.95% | ||
| COLL - EBS | 40% Loosely correlated | -1.36% | ||
| AMPH - EBS | 37% Loosely correlated | +1.00% | ||
| XERS - EBS | 33% Loosely correlated | -3.10% | ||
| VTRS - EBS | 32% Poorly correlated | -1.07% | ||
More | ||||
| Ticker / NAME | Correlation To EBS | 1D Price Change % |
|---|---|---|
| EBS | 100% | -1.43% |
| Pharmaceuticals: Generic industry (83 stocks) | 4% Poorly correlated | -0.84% |